Zacks Investment Research upgraded shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) from a hold rating to a buy rating in a research report sent to investors on Tuesday, October 10th. They currently have $1.50 price target on the biopharmaceutical company’s stock.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
Several other research firms also recently weighed in on RGLS. Needham & Company LLC reiterated a hold rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Wedbush reiterated an ourperform rating and set a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, August 7th. BMO Capital Markets set a $1.00 price objective on Regulus Therapeutics and gave the stock a hold rating in a report on Monday, June 12th. Finally, Chardan Capital downgraded Regulus Therapeutics from a buy rating to a neutral rating in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $3.67.
Shares of Regulus Therapeutics (RGLS) traded down 5.60% during trading on Tuesday, reaching $1.18. 178,035 shares of the company’s stock traded hands. The company has a 50 day moving average price of $1.26 and a 200-day moving average price of $1.23. Regulus Therapeutics has a one year low of $0.79 and a one year high of $3.38. The stock’s market cap is $122.47 million.
Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. On average, equities research analysts expect that Regulus Therapeutics will post ($0.96) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Regulus Therapeutics Inc. (RGLS) Lifted to “Buy” at Zacks Investment Research” was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://weekherald.com/2017/10/20/regulus-therapeutics-inc-rgls-upgraded-to-buy-by-zacks-investment-research.html.
In other Regulus Therapeutics news, CFO Daniel R. Chevallard acquired 54,945 shares of the stock in a transaction on Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, for a total transaction of $49,999.95. Following the purchase, the chief financial officer now directly owns 59,415 shares in the company, valued at $54,067.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joseph P. Hagan bought 219,780 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, with a total value of $199,999.80. Following the transaction, the insider now owns 241,297 shares in the company, valued at approximately $219,580.27. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 549,450 shares of company stock valued at $500,000. 4.80% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in RGLS. Teachers Advisors LLC raised its stake in Regulus Therapeutics by 15.7% during the 4th quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after acquiring an additional 9,804 shares in the last quarter. Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 10.3% during the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 18,600 shares in the last quarter. Royal Bank of Canada raised its stake in Regulus Therapeutics by 12.1% during the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after acquiring an additional 19,934 shares in the last quarter. FMR LLC raised its stake in Regulus Therapeutics by 0.5% during the 2nd quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock valued at $7,862,000 after acquiring an additional 37,489 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its stake in Regulus Therapeutics by 131.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 61,373 shares in the last quarter. 21.94% of the stock is currently owned by institutional investors and hedge funds.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.